Denali-Sanofi scraps mid-stage study for multiple sclerosis drug (updated)

Denali Therapeutics

10/10/2024 22:42

(Adds background throughout)
       Oct 10 (Reuters) - Denali Therapeutics  DNLI.O  said on
Thursday its partner Sanofi  SASY.PA  has discontinued a
mid-stage study testing their experimental drug to treat
multiple sclerosis as it failed to meet the main and secondary
study goals.
    Multiple sclerosis is a debilitating neurological condition
where the immune system degrades the protective covering of
nerves.
    The drug candidate, oditrasertib, co-developed by Sanofi and
Denali, had failed to meet the main goal another mid-stage study
testing it as a treatment for amyotrophic lateral sclerosis, a
fatal neurodegenerative disease.
    Sanofi and Denali had entered into a partnership in 2018, in
which Sanofi agreed to conduct trials to test therapies
developed by Denali for neurological and inflammatory diseases.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Alan
Barona)
 ((Mariam.ESunny@thomsonreuters.com))